SCHEMBL10103349

SCHEMBL10103349

C=C(C)c1ccc(-c2nnc(S)o2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.41
NPC1 O15118 9/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
KDM4E B2RXH2 5/20 0.40
KMT2A Q03164 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37
ADCY1 Q08828 2/20 0.37
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPT P10636 2/20 0.35
TSHR P16473 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13780835 0.81 RAB9A (0.46) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL988353 0.80 NPC1 (0.62) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL13063210 0.79 NPC1 (0.62) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL10103078 0.79 KDM4E (0.66) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL18708515 0.78 NPC1 (0.70) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL25835877 0.77 NPC1 (0.69) RAB9ANPC1SMN1; SMN2HPGDKMT2A
SCHEMBL12948082 0.77 SNCA (0.43) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL9364714 0.76 ACHE (0.47) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL12948027 0.74 MAPT (0.51) RAB9ANPC1SMN1; SMN2HPGDPOLB
SCHEMBL13780842 0.73 HSD17B10 (0.51) RAB9ANPC1SMN1; SMN2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022083-A1 SMALL MOLECULE MODULATORS OF CELL ADHESION ADHEREX TECHNOLOGIES, INC. (CA) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022083-A1 SMALL MOLECULE MODULATORS OF CELL ADHESION CDH1, EPCAM, ICAM1 RAB9A 100/4885NPC1 3435/4885SMN1; SMN2 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.